Real-World MiniMed ™ 780G Advanced Hybrid Closed-Loop Performance Across the Asia-Pacific Region
Open Access
- 28 October 2026
- journal article
- research article
- Published by SAGE Publications in Diabetes Technology & Therapeutics
Abstract
Aims: Diabetes mellitus (types 1 and 2) prevalence in the Asia-Pacific (APAC) region has increased significantly. While real-world evidence demonstrates MiniMed™ 780G (MM780G) system effectiveness and safety in many countries, its use in the APAC region is not well reported. The present study explored MM780G system performance and glycemic outcomes in individuals with diabetes in the APAC region. Methods: CareLink™ personal data uploaded between January 2, 2020, and March 31, 2025, by consenting APAC MM780G system users (all ages) with ≥10 days of continuous glucose monitoring (CGM) data were de-identified, aggregated, and analyzed, including a subanalysis of those using recommended optimal settings (ROS; glucose target of 100 mg/dL with an active insulin time of 2 h, for ≥95% of time). Endpoints were compared between Australia/New Zealand (AUS/NZL) and APAC without AUS/NZL (APAC w/o AUS/NZL) and assessed across quartiles of user-announced total daily carbohydrate (TDCarb). Results: Compared to AUS/NZL ( N = 17,382), APAC w/o AUS/NZL ( N = 8,360) had clinically similar and favorable CGM-derived outcomes, despite a significantly greater mean TDCarb (210.5 g vs. 147.0 g, P < 0.001). Across increasing TDCarb quartiles, for both subregions, time in range improved ( P < 0.001 for both), and time below range <70mg/dL (%TBR) was low (≤2.8%). ROS users showed further glycemic improvement with unchanged %TBR. Conclusions: The MM780G system can effectively manage real-world APAC glycemia irrespective of different TDCarb.Keywords
Funding Information
- MiniMed
This publication has 40 references indexed in Scilit:
- Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: Results from the International diabetes Federation Atlas, 11th Edition, and the T1D Index Version 3.0Diabetes Research and Clinical Practice, 2025
- The automated correction index (ACI), a novel report-derived metric correlated to glucose control and variability in patients with type 1 diabetes on advanced hybrid closed loop therapyDiabetes Research and Clinical Practice, 2025
- Efficacy and Safety of Different Hybrid Closed Loop Systems for Automated Insulin Delivery in People With Type 1 Diabetes: A Systematic Review and Network Meta‐AnalysisDiabetes/Metabolism Research and Reviews, 2024
- Retrospective observational study on real world use of the Minimed™ 780G automated insulin delivery system: Impact of the settings on autocorrection and omitted meal bolusesEndocrinología, Diabetes y Nutrición (English Ed.), 2024
- Basic carbohydrate counting and glycemia in young people with type 1 diabetes in India: A randomized controlled trialNutrition, 2023
- Asia-Pacific consensus recommendations for application of continuous glucose monitoring in diabetes managementDiabetes Research and Clinical Practice, 2023
- Closing the Type 1 Diabetes gap in South-East Asia through government partnership working with non-government organisationsDiabetes Research and Clinical Practice, 2022
- Carbohydrate intake and risk of metabolic syndrome: A dose–response meta-analysis of observational studiesNutrition, Metabolism and Cardiovascular Diseases, 2019
- Diabetes care, glycemic control, and complications in children with type 1 diabetes from Asia and the Western Pacific RegionJournal of Diabetes and its Complications, 2007
- Diabetes mellitus: perspective from the Asia–Pacific regionDiabetes Research and Clinical Practice, 2000